| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
47,934,000 |
| Market
Cap: |
69.02(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$1.45 - $50.59 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Homology Medicines is a genetic medicines company. Co.'s proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors to deliver single administration genetic medicines in vivo either through its gene therapy, Co.'s nuclease-free gene editing modality, or Co.'s gene therapy to express antibodies platform. Co.'s clinical programs include: HMI-102, an investigational gene therapy candidate in clinical development for the treatment of adult patients with phenylketonuria; as well as HMI-103, an investigational gene editing candidate in clinical development for the treatment of patients with PKU.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
26,033 |
| Total Sell Value |
$0 |
$0 |
$0 |
$31,627 |
| Total People Sold |
0 |
0 |
0 |
5 |
| Total Sell Transactions |
0 |
0 |
0 |
9 |
| End Date |
2025-04-03 |
2024-12-31 |
2024-07-02 |
2023-07-03 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Kalowski Lee |
CFO and President |
• – – |
2025-02-24 |
4 |
A |
$0.00 |
$0 |
D/D |
53,250 |
53,250 |
|
- |
|
| Morrison Jodie Pope |
CEO |
• • – |
2025-02-24 |
4 |
A |
$0.00 |
$0 |
D/D |
132,000 |
132,000 |
|
- |
|
| Violette Shelia M. |
Chief Scientific Officer |
• – – |
2025-02-24 |
4 |
A |
$0.00 |
$0 |
D/D |
37,500 |
61,374 |
|
- |
|
| Campagna Jason |
Chief Medical Officer |
• – – |
2025-02-24 |
4 |
A |
$0.00 |
$0 |
D/D |
37,500 |
37,500 |
|
- |
|
| Violette Shelia M. |
Chief Scientific Officer |
• – – |
2024-10-15 |
4 |
OE |
$7.29 |
$43,740 |
D/D |
6,000 |
23,874 |
|
- |
|
| Violette Shelia M. |
Chief Scientific Officer |
• – – |
2024-10-11 |
4 |
OE |
$3.12 |
$14,271 |
D/D |
4,574 |
17,874 |
|
- |
|
| Violette Shelia M. |
Chief Scientific Officer |
• – – |
2024-10-08 |
4 |
OE |
$3.12 |
$41,496 |
D/D |
13,300 |
13,300 |
|
- |
|
| Tzianabos Arthur |
|
– • – |
2024-03-25 |
4 |
S |
$24.20 |
$6,413 |
D/D |
(265) |
7,983 |
|
-127% |
|
| Tzianabos Arthur |
|
– • – |
2024-03-25 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,095 |
8,248 |
|
- |
|
| Michaud Charles Jr |
See Remarks |
• – – |
2024-03-25 |
4 |
AS |
$24.20 |
$1,815 |
D/D |
(75) |
927 |
|
127% |
|
| Alloway Paul |
See Remarks |
• – – |
2024-03-25 |
4 |
AS |
$24.21 |
$6,488 |
D/D |
(268) |
2,596 |
|
127% |
|
| Grayzel David S. |
|
– • – |
2024-03-25 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
2,092,106 |
|
127% |
|
| Atlas Venture Associates Opportunity Ii, Llc |
|
– – • |
2024-03-25 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
1,227,845 |
|
127% |
|
| Atlas Venture Associates Opportunity Ii, Llc |
|
– – • |
2024-03-25 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
864,261 |
|
127% |
|
| Orbimed Capital Gp Vii Llc |
|
– • • |
2024-03-25 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
2,252,987 |
|
127% |
|
| Lundberg Sven Ante |
|
– • – |
2024-03-25 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
1,200 |
|
127% |
|
| Laporte Kathleen |
|
– • – |
2024-03-25 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
5,431 |
|
127% |
|
| Violette Shelia M. |
Chief Scientific Officer |
• – – |
2024-03-25 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
36,277 |
|
127% |
|
| Xu Diyong |
|
– • • |
2024-03-25 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
2,252,987 |
|
127% |
|
| Alloway Paul |
See Remarks |
• – – |
2024-03-25 |
4 |
OE |
$0.00 |
$0 |
D/D |
23,530 |
51,566 |
|
- |
|
| Michaud Charles Jr |
See Remarks |
• – – |
2024-03-25 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,448 |
18,046 |
|
- |
|
| Tzianabos Arthur |
|
– • – |
2024-01-09 |
4 |
AS |
$0.57 |
$7,445 |
D/D |
(13,037) |
128,778 |
|
155% |
|
| Michaud Charles Jr |
See Remarks |
• – – |
2024-01-03 |
4 |
AS |
$0.57 |
$975 |
D/D |
(1,708) |
11,598 |
|
168% |
|
| Alloway Paul |
See Remarks |
• – – |
2024-01-03 |
4 |
AS |
$0.57 |
$4,120 |
D/D |
(7,280) |
28,036 |
|
168% |
|
| Tzianabos Arthur |
|
– • – |
2024-01-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
33,420 |
141,815 |
|
- |
|
157 Records found
|
|
Page 1 of 7 |
|
|
